Soluble 3′,6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period

Journal of Medicinal Chemistry

Volumn 51, Issue 20, 2008, Pages 6421-6431

  Vougogiannopoulou, Konstantina ^a   Ferandin, Yoan ^b   Bettayeb, Karima ^b   Myrianthopoulos, Vassilios ^a   Lozach, Olivier ^b   Fan, Yunzhen ^c   Johnson, Carl Hirschie ^c   Magiatis, Prokopios ^a   Skaltsounis, Alexios Leandros ^a   Mikros, Emmanuel ^a   Meijer, Laurent ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b STATION BIOLOGIQUE   (France)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 BROMOINDIRUBIN 3' [O (2 BROMOETHYL)OXIME]; 6 BROMOINDIRUBIN 3' [O (2 DIETHYLAMINOETHYL)OXIME]; 6 BROMOINDIRUBIN 3' [O (2 DIMETHYLAMINOETHYL)OXIME]; 6 BROMOINDIRUBIN 3' [O (2 HYDROXYETHYL)OXIME]; 6 BROMOINDIRUBIN 3' [O (2 MORPHOLIN 1 YLETHYL)OXIME]; 6 BROMOINDIRUBIN 3' [O (2 PIPERAZIN 1 YLETHYL)OXIME]; 6 BROMOINDIRUBIN 3' [O (2 PYRROLIDIN 1 YLETHYL)OXIME]; 6 BROMOINDIRUBIN 3' [O (2,3 DIHYDROXYPROPYL)OXIME]; 6 BROMOINDIRUBIN 3' [O (N,N DIETHYLCARBAMYL)OXIME]; 6 BROMOINDIRUBIN 3' [O [2 (4 METHYLPIPERAZIN 1 YL)ETHYL]OXIME]; 6 BROMOINDIRUBIN 3' [O [2 [4 (2 HYDROXYETHYL)PIPERAZIN 1 YL]ETHYL]OXIME]; 6 BROMOINDIRUBIN 3' [O [2 [4 (2 METHOXYETHYL)PIPERAZIN 1 YL]ETHYL]OXIME]; 6 BROMOINDIRUBIN 3' [O [2 [4 [2 (2 HYDROXYETHOXY)ETHYL]PIPERAZIN 1 YL]ETHYL]OXIME]; 6 BROMOINDIRUBIN 3' [O [2 [N METHYL N (2,3 DIHYDROXYPROPYL)AMINO]ETHYL]OXIME]; 6 BROMOINDIRUBIN 3' [O [2 [N,N (2 HYDROXYETHYL)AMINO]ETHYL]OXIME]; 6 BROMOINDIRUBIN 3' OXIME DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDIRUBIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BETA CATENIN; BROMINE DERIVATIVE; INDIRUBIN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL ASSAY; CIRCADIAN RHYTHM; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOPATHOGENIC EFFECT; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; RAT; REGULATORY MECHANISM; ANIMAL; BINDING SITE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HYDROPHOBICITY; METABOLISM; PHOSPHORYLATION; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; BETA CATENIN; BINDING SITES; BROMINE COMPOUNDS; CELL LINE; CIRCADIAN RHYTHM; CRYSTALLOGRAPHY, X-RAY; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYDROPHOBICITY; INDOLES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 54549104866     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800648y     Document Type: Article

References (49)

1. Doble, B. W.; Woodgett, J. R. GSK-3: tricks of the trade for a multitasking kinase. J. Cell Sci. 2003, 116, 1175-1186.
2. Jope, R. S.; Johnson, G. V. W. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29, 95-102.
3. Dajani, R.; et al. Crystal structure of glycogen synthase kinase 3β: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001, 105, 721-732.
4. ter Haar, E.; et al. Structure of GSK3β reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 2001, 8, 593-596.
5. Kockeritz, L.; Doble, B.; Patel, S.; Woodgett, J. R. Glycogen synthase kinase-3: an overview of an overachieving protein kinase. Curr. Drug Targets 2006, 7, 1377-88.
6. Droucheau, E.; Primot, A.; Thomas, V.; Mattei, D.; Knockaert, M.; Richardson, C.; Sallicandro, P.; Alano, P.; Jafarshad, A.; Baratte, B.; Kunick, C.; Parzy, D.; Pearl, L.; Doerig, C.; Meijer, L. Plasmodium falciparum glycogen synthase kinase-3, molecular model, expression, intracellular localisation and selective inhibitors. Biochim. Biophys. Acta: Proteins and Proteomics 2004, 1697, 181-196.
7. Xingi, E.; Smirlis, D.; Bisti, S.; Myrianthopoulos, V.; Magiatis, P.; Meijer, L.; Mikros, E.; Alexios-Skaltsounis, A. L.; Soteriadou, K. Role of Leishmania donovani glycogen synthase kinase-3β in parasite cellular processes: a potential drug target. Mol. Pharmacol. 2008, in press.
8. Kassir, Y.; Rubin-Bejerano, I.; Mandel-Gutfreund, Y. The Saccharomyces cerevisiae GSK-3 beta homologs. Curr. Drug Targets 2006, 7, 1455-1465.
9. Muyllaert, D.; Kremer, A.; Jaworski, T.; Borghgraef, P.; Devijver, H.; Croes, S.; Dewachter, I.; Van Leuven, F. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology. Genes Brain Behav. 2008, 7 (Suppl 1), 57-66.
10. Hooper, C.; Killick, R.; Lovestone, S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 2008, 104, 1433-1439.
11. Avila, J.; Hernández, F. GSK-3 inhibitors for Alzheimer's disease. Expert Rev. Neurother. 2007, 7, 1527-1533.
12. Lovestone, S.; Killick, R.; Di Forti, M.; Murray, R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 2007, 30, 142-149.
13. Rowe, M. K.; Wiest, C.; Chuang, D. M. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci. Biobehav. Rev. 2007, 31, 920-931.
14. Tanabe, K.; Liu, Z.; Patel, S.; Doble, B. W.; Li, L.; Cras-Méneur, C.; Martinez, S. C.; Welling, C. M.; White, M. F.; Bernal-Mizrachi, E.; Woodgett, J. R.; Permutt, M. A. Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol. 2008, 6, e37.
15. Sugden, P. H.; Fuller, S. J.; Weiss, S. C.; Clerk, A. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br. J. Pharmacol. 2008, 153 (Suppl 1), S137-S153.
16. Kerkelä, R.; Woulfe, K.; Force, T. Glycogen synthase kinase-3beta: actively inhibiting hypertrophy. Trends Cardiovasc. Med. 2007, 17, 91-96.
17. Obligado, S. H.; Ibraghimov-Beskrovnaya, O.; Zuk, A.; Meijer, L.; Nelson, P. J. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int. 2008, 73, 684-690.
18. Dugo, L.; Collin, M.; Thiemermann, C. Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock 2007, 27, 113-123, Erratum in: Shock 2007, 27, 709.
19. Ougolkov, A. V.; Billadeau, D. D. Targeting GSK-3: a promising approach for cancer therapy. Future Oncol. 2006, 2, 91-100.
20. Sato, N.; Meijer, L.; Skaltsounis, L.; Greengard, P.; Brivanlou, A. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3 specific inhibitor. Nat. Med. 2004, 10, 55-63.
21. Martinez, A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med. Res. Rev. 2008, 28, 773-796.
22. Patel, D. S.; Dessalew, N.; Iqbal, P.; Bharatam, P. V. Structure-based approaches in the design of GSK-3 selective inhibitors. Curr. Protein Pept. Sci. 2007, 8, 352-364.
23. Cohen, P.; Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discovery 2004, 3, 479-487.
24. Meijer, L.; Flajolet, M.; Greengard, P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 2004, 25, 471-480.
25. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Mandelkow, E.-M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two kinases involved in abnormal tau phosphorylation in Alzheimer's disease: a property common to most CDK inhibitors. J. Biol. Chem. 2001, 276, 251-260.
26. Meijer, L., Guyard, N., Skaltsounis, L. A., Eisenbrand, G., Eds. Indirubin: The Red Shade of Indigo; Life in Progress: Station Biologique, Roscoff, France, 2006; 297 pp, 27 chapters.
27. Meijer, L.; Skaltsounis, A. L.; Magiatis, P.; Polychonopoulos, P.; Knockaert, M.; Leost, M.; Ryan, X. P.; Vonica, C. D.; Brivanlou, A.; Dajani, R.; Tarricone, A.; Musacchio, A.; Roe, S. M.; Pearl, L.; Greengard, P. GSK-3 selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 2003, 10, 1255-1266.
28. Polychronopoulos, P.; Magiatis, P.; Skaltsounis, L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S. M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. 2004, 47, 935-946.
29. Ribas, J.; Bettayeb, K.; Ferandin, Y.; Garrofé-Ochoa, X.; Knockaert, M.; Totzke, F.; Schachtele, C.; Mester, J.; Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L.; Boix, J.; Meijer, L. 7-Bromoindirubin- 3′-oxime induces caspase-independent cell death. Oncogene 2006, 25, 6304-6318.
30. Jautelat, R.; Brumby, T.; Schafer, M.; Briem, H.; Eisenbrand, G.; Schwahn, S.; Kruger, M.; Lucking, U.; Prien, O.; Siemeister, G. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. Chem. Biochem. 2005, 6, 531-540.
31. Merz, K. H.; Schwahn, S.; Hippe, F.; Mühlbeyer, S.; Jakobs, S.; Eisenbrand, G. Novel indirubin derivatives, promising antitumor agents inhibiting cyclin-dependent kinases. Int. J. Clin. Pharmacol. Ther. 2004, 42, 656-658.
32. Hoessel, R.; Leclerc, S.; Endicott, J.; Noble, M.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999, 1, 60-67.
33. Davies, T. G.; Tunnah, P.; Meijer, L.; Marko, D.; Eisenbrand, G.; Endicott, J. A.; Noble, M. E. M. Inhibitor binding to active and inactive CDK2. The crystal structure of a CDK2-cyclin A/indirubin-5-sulphonate. Structure 2001, 9, 389-397.
34. Mapelli, M.; Massimiliano, L.; Crovace, C.; Seeliger, M.; Tsai, L. H.; Meijer, L.; Musacchio, A. Mechanism of CDK5/p25 binding by CDK inhibitors. J. Med. Chem. 2005, 48, 671-679.
35. Holten, S.; Merckx, A.; Burgess, D.; Doerig, C.; Noble, M.; Endicott, J. Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition. Structure 2003, 11, 1329-1337.
36. Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. M.; Flocco, M. Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol. 2003, 33, 393-407.
37. Myrianthopoulos, V.; Magiatis, P.; Ferandin, Y.; Skaltsounis, A. L.; Meijer, L.; Mikros, E. An integrated computational approach to the phenomenon of potent and selective inhibition of Aurora kinases B and C by a series of 7-substituted indirubins. J. Med. Chem. 2007, 50, 4027-4037.
38. Ferandin, Y.; Bettayeb, K.; Kritsanida, M.; Lozach, O.; Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L.; Meijer, L. 3′-Substituted, 7-halogenoindirubins, a new class of cell death inducing agents. J. Med. Chem. 2006, 49, 4638-4649.
39. Beauchard, A.; Ferandin, Y.; Frère, S.; Lozach, O.; Blairvacq, M.; Meijer, L.; Thiéry, V.; Besson, T. Synthesis of novel 5- substituted indirubins as potential inhibitor of protein kinases. Bioorg. Med. Chem. 2006, 14, 6434-6443.
40. Moon, M. J.; Lee, S. K.; Lee, J. W.; Song, W. K.; Kim, S. W.; Kim, J. I.; Cho, C.; Choi, S. J.; Kim, Y. C. Synthesis and structure-activity relationships of novel indirubin derivatives as potent antiproliferative agents with CDK2 inhibitory activities. Bioorg. Med. Chem. 2006, 14, 237-246.
41. Knockaert, M.; Blondel, M.; Bach, S.; Leost, M.; Elbi, C.; Hager, G.; Naggy, S. R.; Han, D.; Denison, M.; French, M.; Ryan, X. P.; Magiatis, P.; Polychronopoulos, P.; Greengard, P.; Skaltsounis, L.; Meijer, L. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene 2004, 23, 4400-4412.
42. Stewart, J. J. P. MOPAC-A semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
43. Mohamadi, F.; Richards, N. G.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macromodel: an intergrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
44. Martinek, S.; Inonog, S.; Manoukian, A. S.; Young, M. W. A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 2001, 105, 769-779.
45. Iitaka, C.; Miyazaki, K.; Akaike, T.; Ishida, N. A role for glycogen synthase kinase-3beta in the mammalian circadian clock. J. Biol. Chem. 2005, 280, 29397-29402.
46. Izumo, M.; Sato, T. R.; Straume, M.; Johnson, C H. Quantitative analyses of circadian gene expression in mammalian cell cultures. PLoS Comput. Biol. 2006, 2, e136.
47. Primot, A.; Baratte, B.; Gompel, M.; Borgne, A.; Liabeuf, S.; Romette, J. L.; Costantini, F.; Meijer, L. Purification of GSK-3 by affinity chromatography on immobilised axin. Protein Expr. Purif. 2000, 20, 394-404.
48. Ribas, J.; Boix, J. Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs. Exp. Cell Res. 2004, 295, 9-24.
49. Leost, M.; Schultz, C.; Link, A.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E.-M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderovitz, A.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 2000, 267, 5983-5994.